12:00 AM
 | 
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ThermoDox heat-activated liposome: Phase III data

The double-blind, sham-controlled, international Phase III HEAT trial in 701 patients with intermediate, unresectable HCC showed that 50 mg/m 2 IV ThermoDox plus radiofrequency ablation missed the primary endpoint of improving PFS vs. radiofrequency ablation alone. The trial was designed to show a 33% improvement in PFS with 80% power and a p-value of 0.05. ThermoDox was well tolerated with no unexpected serious adverse events...

Read the full 303 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >